ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.